New hope for kids with Crohn's: drug shows promise in small trial

NCT ID NCT01580670

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jan 11, 2026 · Last updated May 12, 2026 · Updated 18 times

Summary

This study tested a drug called TA-650 (similar to infliximab) in 14 children with moderate to severe Crohn's disease. The goal was to see if the drug could reduce disease activity and improve symptoms. Children received the drug by infusion at regular intervals over nearly a year. The study found that some children experienced a meaningful reduction in symptoms, but because Crohn's is a chronic condition, ongoing treatment is typically needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Investigational site

Chūbu, Japan
Investigational site

Hokkaido, Japan
Investigational site

Hokuriku, Japan
Investigational site

Kanto, Japan
Investigational site

Kinki, Japan
Investigational site

Kyusyu, Japan
Investigational site

Tōhoku, Japan

Conditions

Explore the condition pages connected to this study.

PEDIATRIC CROHN'S DISEASE